Linking systemic angiogenic factors (VEGF, angiogenin, TIMP-2) and Doppler ultrasound to anti-inflammatory treatment in rheumatoid arthritis

Joint Bone Spine

Volumn 80, Issue 3, 2013, Pages 270-273

  Strunk, Johannes ^a   Rumbaur, Carola ^b   Albrecht, Katinka ^c   Neumann, Elena ^b   Müller Ladner, Ulf ^b  

^a Krankenhaus Porz am Rhein   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c Köpenicker Street 48/49 ^*  (Germany)

Author keywords

Angiogenesis factor; Doppler ultrasonography; Rheumatoid arthritis; VEGF

Indexed keywords

ADALIMUMAB; ANGIOGENIN; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VASCULOTROPIN; ANTIINFLAMMATORY AGENT; PANCREATIC RIBONUCLEASE; TIMP2 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; DOPPLER FLOWMETRY; FEMALE; HUMAN; MALE; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; DRUG EFFECTS; DRUG MONITORING; ECHOGRAPHY; MIDDLE AGED; PROCEDURES; SYNOVIUM; WRIST;

AGED; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; DRUG MONITORING; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; RIBONUCLEASE, PANCREATIC; SYNOVIAL MEMBRANE; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR NECROSIS FACTOR-ALPHA; ULTRASONOGRAPHY, DOPPLER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WRIST JOINT;

EID: 84878368793     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.09.001     Document Type: Article

References (32)

1. Koch A.E. Review: angiogenesis - implications for rheumatoid arthritis. Arthritis Rheum 1998, 41:951-962.
2. Walsh D.A. Angiogenesis and arthritis. Rheumatology 1999, 38:103-112.
3. Paleolog E.M. Angiogenesis: a critical process in the pathogenesis of RA - a role of VEGF?. Br J Rheumatol 1996, 35:917-919.
4. Nagashima M., Yoshino S., Ishiwata T., et al. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol 1995, 22:1624-1630.
5. Grothey A., Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009, 6:507-518.
6. Szekanecz Z., Besenyei T., Paragh G., et al. New insights in synovial angiogenesis. Joint Bone Spine 2010, 77:13-19.
7. Wauke K., Nagashima M., Ishiwata T., et al. Expression and localization of vascular endothelial growth factor-C in rheumatoid arthritis synovial tissue. J Rheumatol 2002, 29:34-38.
8. Kasama T., Shiozawa F., Kobayashi K., et al. Vascular endothelial growth factor expression by activated synovial leukocytes in rheumatoid arthritis. Arthritis Rheum 2001, 44:2512-2524.
9. Harada M., Mitsuyama K., Yoshida H., et al. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998, 27:377-380.
10. Adams S.A., Subramanian V. The angiogenins: an emerging family of ribonuclease related proteins with diverse cellular functions. Angiogenesis 1999, 3:189-199.
11. Lioté F., Champy R., Moenner M., et al. Elevated angiogenin levels in synovial fluid in patients with inflammatory arthritis and secretion of angiogenin by cultured synovial fibroblast. Clin Exp Immunol 2003, 132:163-168.
12. Bahudhanapati H., Zhang Y., Sidhu S.S., et al. Phage display of tissue inhibitor of metalloproteinase-2 (TIMP-2): identification of selective inhibitors of collagenase-1 (metalloproteinase 1 [MMP-1]). J Biol Chem 2011, 286:31761-31770.
13. Rooney T., Roux-Lombard P., Veale D.J., et al. Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade. Ann Rheum Dis 2010, 69:706-714.
14. Taylor P.C., Steuer A., Gruber J., et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 2004, 50:1107-1116.
15. Hau M., Kneitz C., Tony H.P., et al. High resolution ultrasound detects a decrease in pannus vascularisation of small finger joints in patients with rheumatoid arthritis receiving treatment with soluble tumor necrosis factor alpha receptor (etanercept). Ann Rheum Dis 2002, 61:55-58.
16. Filippucci E., Farina A., Carotti M., et al. Grey scale and power Doppler sonographic changes induced by intra-articular steroid injection treatment. Ann Rheum Dis 2004, 63:740-743.
17. Fiocco U., Ferro F., Vezzu M., et al. Rheumatoid and psoriatic knee synovitis: clinical, grey scale, and power Doppler ultrasound assessment of the response to etanercept. Ann Rheum Dis 2005, 64:899-905.
18. Paleolog E.M., Young S., Stark A.C., et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998, 41:1258-1265.
19. Nakahara H., Song J., Sugimoto M., et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003, 48:1521-1529.
20. Ballara S., Taylor P.C., Reusch P., et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001, 44:2055-2064.
21. Strunk J., Bundke E., Lange U. Anti-TNF-α antibody infliximab and glucocorticoids reduce serum vascular endothelial growth factor (VEGF) levels in patients with rheumatoid arthritis - a pilot study. Rheumatol Int 2006, 26:252-256.
22. Kawashiri S.Y., Kawakami A., Iwamoto N., et al. The power Doppler ultrasonography score from 24 synovial sites or 6 simplified synovial sites, including the metacarpophalangeal joints, reflects the clinical disease activity and level of serum biomarkers in patients with rheumatoid arthritis. Rheumatology 2011, 50:962-965.
23. Strunk J., Heinemann E., Schmidt K.L., et al. A new approach to studying angiogenesis in rheumatoid arthritis by means of power Doppler sonography and measurement of serum vascular endothelial growth factor. Rheumatology 2004, 43:1480-1483.
24. Gullick N.J., Church L.D., Jayaraj D.M., et al. Linking power Doppler ultrasound to the presence of Th 17 cells in the rheumatoid arthritis joint. PLoS ONE 2010, 5:e12516.
25. Strunk J., Strube K., Rumbaur C., et al. Inter-observer agreement in two- and three-dimensional power Doppler sonographic assessment of synovial vascularity during anti-inflammatory treatment in patients with rheumatoid arthritis. Ultraschall Med 2007, 28:409-415.
26. Rasband W.S. Image J, National Institutes of Health 1997-2005, Bethesda, Maryland, USA. http://rsb.info.nih.gov/ij/.
27. Maini R.N., Taylor P.C., Paleolog E., et al. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis 1999, 58:I56-I60.
28. Albrecht K., Müller-Ladner U., Strunk J. Quantification of the synovial perfusion in rheumatoid arthritis using Doppler ultrasonography. Clin Exp Rheumatol 2007, 25:630-638.
29. Vreju F., Ciurea M., Roşu A., et al. Power Doppler sonography, a non-invasive method of assessment of the synovial inflammation in patients with early rheumatoid arthritis. Rom J Morphol Embryol 2011, 52:637-643.
30. Lee S.S., Joo Y.S., Kim W.U., et al. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 2001, 19:321-324.
31. Semerano L., Clavel G., Assier E., et al. Blood vessels, a potential therapeutic target in rheumatoid arthritis?. Joint Bone Spine 2011, 78:118-123.
32. Taylor P.C. Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. Rheumatology 2005, 44:721-728.